Indivior PLC (LSE:INDV), a company specialising in addiction treatment, has settled a legal dispute with Actavis, a part of Teva Pharmaceuticals.
The disagreement was about Actavis's plan to make a generic version of a drug combining buprenorphine and a naloxone sublingual film.
As part of the settlement, Indivior has granted Actavis a licence to the patent covering the film, which would allow Actavis to start selling this generic drug in the US, but not before 31 January 2025.